The Western Development Commission today announced it has invested €2million in Atlantic Therapeutics, the Galway-based company pioneering a non-invasive, wearable treatment for urinary incontinence.
This is the largest single investment the WDC Investment Fund have made to date and is complemented by returning investors Seroba Life Sciences, Earlybird, LSP, Andera Partners and Atlantic Bridge, who continue their ongoing support for Atlantic Therapeutics with a substantial undisclosed investment.
The financing will support the expansion of the company’s commercialization activities in the core US and UK markets for its INNOVO technology to treat urinary incontinence. Also known as bladder weakness, urinary incontinence is a stigmatised condition that impacts one in three women worldwide, having a profoundly negative impact on quality and enjoyment of life.
Atlantic Therapeutics has established the INNOVO brand as the leading innovation in non-invasive, wearable neuromuscular electrical stimulation. The device acts to strengthen the pelvic floor and thereby treat the underlying cause of bladder weakness.
The technology has offered hope to millions of women worldwide whose only option to deal with bladder leaks has to been to use feminine hygiene pads.
The Western Development Commission’s €75m Investment Fund is an Evergreen investment fund, providing seed and venture capital and loan finance to SMEs, micro-enterprises, social enterprises and community projects across the Western Region. To date, it has invested in more than 200 enterprises supporting over 5,000 jobs and leveraging over a quarter of a billion investment for western enterprises.
Commenting in the investment, Gillian Buckley, Investment Manager at the Western Development Commission said:
The WDC Investment Fund has helped support the position of the West of Ireland as a start-up hub for indigenous medtech and lifescience companies building on the region’s reputation as a global centre of excellence. Atlantic Therapeutics is our 35th life science investment making the WDC Investment Fund one of the largest medtech/lifescience investors in the country. The WDC is an impact investor so we seek not only a financial return on investment but also seek a socio-economic impact. Atlantic Therapeutics offers both, it will support high quality jobs in Galway and Mayo as well as addressing a significant women’s heathcare issue.
Atlantic Therapeutics CEO, Susan Trent commented: “We are thrilled to have such strong support from the Western Development Commission and I look forward to working closely with them on realising the incredible potential of our brand. This significant investment is a major vote of confidence in the potential and ambition of our company, and demonstrates our deep commitment to the West of Ireland. We are extremely proud to be bringing the first-in-world INNOVO technology to several key global markets from our base in Galway, one of the leading medical device hubs in the world. We firmly believe that INNOVO represents a paradigm shift in the $13bn urinary incontinence market when compared to the current sub-optimal choices. This investment will help us to accelerate global momentum for INNOVO, and allow us to amplify the launch of our next generation innovation later this year.”
Tomás Ó Síocháin, CEO of the WDC welcomed on the investment “The development of INNOVO is an opportunity to improve the quality of life for a huge number of women worldwide. More broadly, it continues to underline the strength of Galway as a global medtech hub, driving innovation and entrepreneurship and building resilience across the region.
For further information or to arrange interviews, please contact
Allan Mulrooney, Head of Communications
allanmulrooney@wdc.ie or +353 87 334 3713
